

2nd Annual



The Neurotech Industry Investing & Partnering Conference

Advances in Drugs, Devices & Diagnostics for the Brain and Nervous System

May 17-18, 2007 – Westin San Francisco Airport, Millbrae CA

Join leading investors, executives, and entrepreneurs developing of new treatments and diagnostics for the brain and nervous system in shaping the future of their organization and the industry.

The 2nd annual conference features over 30 cutting edge company presentations, keynotes on the state of the neurotech industry, and panel discussions on a comprehensive selection of neurotech topics of interest to biotech, medtech, and IT investors and executives.

- Find out about new product licensing and partnering opportunities
- Learn what venture and strategic investors are looking for
- Discover emerging technologies and companies
- Learn about cutting edge research and funding opportunities
- Find out who is investing in neurotech and why

Hear about next generation treatments for Alzheimer's, addiction, anxiety, depression, epilepsy, insomnia, multiple sclerosis, obesity, pain, Parkinson's, schizophrenia, stroke and other brain-related illnesses.

Advisory Board:

Sam Barondes, MD, Director, Center Neurobiology & Psychiatry, UCSF

Zack Lynch, Executive Director, Neurotechnology Industry Organization

Nola Masterson, Managing Director, Science Futures

Bob Metcalfe, PhD, Leadership Board, McGovern Institute for Brain Research, MIT

Dan O'Connell, Director, NeuroVentures Capital

Roger Quy, PhD, General Partner, Technology Partners

Nandini Tandon, PhD, Venture Partner, MDS Capital

Gold Sponsors:

NIXON PEABODY
ATTORNEYS AT LAW

NIO
Neurotechnology
Industry Organization

NASDAQ[®]

K&L | GATES

Kirkpatrick & Lockhart Preston Gates Ellis LLP

REVERE[™]

Register Before April 13th for Early Rates at www.neuroinsights.com

Thursday May 17, 2007

 7:00 - 8:00 AM

Breakfast & Registration

 8:00 - 8:30 AM

The Global Neurotech Industry

NeuroInsights reveals updated proprietary market data, revenue projections, and industry trends.

Zack Lynch
Executive Director, Neurotechnology Industry Organization

 8:30 - 9:15 AM

Investing in Neurotech

A diverse panel of neurotech investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are the benefits and risks of business models in devices, pharmaceuticals, and diagnostics?

Ellen Baron
Partner, Oxford Bioscience Partners

Nicola Campbell
General Partner, Sofinnova

Roger Quy
General Partner, Technology Partners

Matthew Perry
Portfolio Manager
Biotechnology Value Fund

Moderator: Casey Crawford Lynch
Managing Director, NeuroInsights

 9:15 - 10:15 AM

Epilepsy and Neuropathic Pain

Antiepileptics are one of the largest revenue categories in neurotech. This is due in part to off-label prescribing for neuropathic pain and bipolar disorder. What are the latest advances in drugs and devices?

William Armiger
CEO, NeuroGenomeX

Frank Fischer
President & CEO, Neuropace

Leo Liu
President and CSO, Cambria Biosciences

Rich Masterson
Vice President and General Manager
Valeant Pharmaceuticals

Session Chair: Warren Lammert
Founder
Epilepsy Therapy Development Project

 10:15 - 10:45 AM

Refreshment Break

 10:45 - 12:00 PM

Advances in Neuropsychiatry

Schizophrenia, anxiety, depression, and other neuropsychiatric illnesses represent a large portion of the neurotech market. What are the most promising next generation treatments? How will devices change the treatment landscape?

Jeff Bacha
Executive VP and COO, Clera

Mark Bausinger
CFO, Neuronetics

Barry Brand
CEO, CeNeRx Biopharma

Mark Varney
COO & CSO, Cortex Pharmaceuticals

Session Chair: Harry Tracy
Publisher, NeuroInvestment

 12:00 - 1:30 PM Lunch Keynote

Dr. Michael Huerta
Associate Director
National Institutes of Mental Health

Accelerating the "Decade of Translation"

 1:30 - 2:30 PM

Stroke: Prevention, Protection, and Recovery

Stroke is generally considered one of the highest risk disease categories for development due to a heterogeneous patient population, short therapeutic window, and poorly defined therapeutic endpoints. A clear unmet

need in prevention, protection, and recovery continues to drive innovation and investment in diverse approaches to new drugs and devices.

Alan Levy
President & CEO, Northstar Neuroscience

Alan Moore
President & CEO, Stem Cell Therapeutics

Peter Rule
Chairman & CEO, Ekos

Andrew Weiss
President and CEO, CoAxia

Session Chair: Frank Eeckman
Neurotech Insights, Centient Biotech

 2:30 - 3:15 PM

Regulatory and Reimbursement Issues Panel

Working with the FDA for approval and Medicare for reimbursement is critical to the success of any neurotech venture. The moderator will lead an insider panel in an in-depth discussion of issues facing the industry and tactics for improving development times and successfully navigating the path to approval and reimbursement.

Lauren Choi
NIO Policy Council, Buchanan Ingersoll & Rooney

Shawn P. Lunney
Vice President Market Development
Cyberonics

Cynthia Rask
Former FDA Director, Division of Clinical Evaluation & Pharmacology/Toxicology

Moderator: Jill Alvarez
Nixon Peabody, LLP

 3:15 - 3:45 PM

Refreshment Break

 3:45 - 4:45 PM

Growth of Specialty Neuropharma

Focused companies that in-license later stage product have become

popular with investors. These companies have the potential to leverage targeted salesforces while virtually eliminating R&D expenses. What are the long term prospects for specialty neuropharma companies?

Joern Aldag
CEO, Evotec

Vincent Simmon
President & CEO, Xytis Pharmaceuticals

Rick Stewart
CEO, Amarin

Tom Woiwode
VP Business Development, Synosia

Session Chair: Charles Duncan
Managing Director, JMP Securities

4:45 – 5:30 PM

Brain Fitness through Software and Neurofeedback

Spurred by the discovery of neuroplasticity and the aging baby boomer population software companies, large and small, are venturing into the realm of therapy and cognitive fitness. Investors are drawn by the potential of the large markets, lack of FDA involvement, and scalability of the software model.

John Hollister
CEO, EEG Spectrum

Jonas Jendi
CEO, Cogmed

Jeff Zimman
President & CEO, Posit Science

Session Chair: Alvaro Fernandez
CEO & Co-Founder, SharpBrains

5:30 – 6:30 PM

Wine Tasting Reception Sponsored by:



Friday May 18, 2007

7:30 - 8:30 AM

Breakfast & Registration

8:30 – 9:15 AM

Partnering and Licensing in Neurotech

Big pharma, biotech and medtech are increasingly looking for innovative product candidates to fill pipelines. What are current trends in strategic alliances and partnering?

Thomas Heffner
Executive Director, Worldwide Business Development, Pfizer

Lothar Krinke
Vice President of Business Development
Medtronic Neurological

David Paterson
Sr. Director, Business Development
Sepracor

Luca Santarelli
Head of CNS Therapy, Roche

Moderator: Christine de los Reyes
BioTechPartnering Solutions

9:15 – 10:00 AM

The Future of Obesity: Drugs and Devices on the Horizon

New drugs with fewer side effects are on the horizon for treatment of obesity. Companies developing neurostimulation devices are also in hot pursuit with major funding in 2007.

Michael Cowley
Chief Scientific Officer, Orexigen

Andrew Uprichard
President, Epix Pharmaceuticals

Chuck Brynelsen*
CEO, Inrapace

Session Chair: Dan O'Connell
Director, NeuroVentures Capital

10:00 - 10:30 AM

Refreshment Break

10:30 - 11:15 AM

Neurodiagnostics: Biomarkers and Brain Imaging

There is increasing demand among patient populations, insurers, and even pharmaceutical companies for improved neurodiagnostics. Reliable biomarker and imaging tests have the potential to improve patient selection and decrease clinical trial timelines.

Peter Kingma
Vice President, Molecular Imaging
Division, Seimens Medical

Alan Rudolph
CEO, Adlyfe

Daniel Skovronsky
CEO, Avid Radiopharmaceuticals

Session Chair: Zack Lynch
Executive Director, Neurotech Indust. Org.

11:15 - 12:30 PM

Alzheimer's: Symptomatic and Disease Modifying Approaches

As the population ages, the market for Alzheimer's treatments is exploding. What are the latest strategies for treating memory decline? What are the preclinical & clinical challenges?

Scott Harkonen
President & CEO, CoMentis

David Hung
President & CEO, Medivation

Steve Orndorff
President & CEO, Accera

David Summa
President & CEO, Acumen

Session Chair: Casey Crawford Lynch
Managing Director NeuroInsights

Conference Concludes

12:30- 2:30 PM

NIO Annual Meeting & Partnering Lunch -

Open to Members & Potential Members
Limited seating - Sign up at
www.neurotechindustry.org



Reserve Your Place Now!

Register for **The Neurotech Industry Conference** in one of the following ways:

Internet: Log on to www.neuroinsights.com and click on The Neurotech Industry Conference

Mail: You can mail your completed registration form (or a photocopy) along with your payment to:

NeuroInsights
315 30th Street
San Francisco, CA 94131

*Make check payable to NeuroInsights

Fax: 415-358-5888

NeuroInsights will acknowledge your registration with a confirmation email.

Email: conference@neuroinsights.com

Phone: 415-229-3225

Cancellation: Cancellations received in writing by NeuroInsights before April 15th will receive a refund, minus a \$300 administration charge. Thereafter, refunds are not available. Substitutions may be made at any time by calling NeuroInsights at 415-229-3225.

Conference Venue:

Westin San Francisco Airport
1 Old Bayshore Highway
Millbrae, CA 94030
Tel: 650-692-3500
Fax: 650-872-8111

To receive the special hotel rate of \$169, mention "The Neurotech Industry Conference." Rate is available on a limited number of rooms until May 2, 2007.

Directions: From San Francisco International Airport - Take Highway 101 South and exit at Millbrae East. Follow the exit ramp around, and then turn right onto Old Bayshore Highway.

Sponsors:

For more information contact
Casey Lynch
415-229-3225
Conference@neuroinsights.com
www.neuroinsights.com

Please Register Me:

	Full Conference	\$1395
	Full Conference Emerging Company*	\$1195
	Full Conference Academic or Nonprofit	\$895

*Emerging company= pre-revenue with only seed or series A financing

Name _____
Title _____
Company _____
Address _____
City/State/Zip _____
Telephone _____ Fax _____
Email for confirmation _____
How did you hear about the conference? _____

Please invoice me:
Payment enclosed:
Charge it on my: Visa Mastercard American Express

Name on Card _____
Billing Address _____
Card No. _____ Exp. Date _____
Signature _____



315 30th Street
San Francisco, CA 94131